

September 12, 2024

The Listing Department
BSE Limited
Phiroze Jeejebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015 (“SEBI Listing Regulations”)

Pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform that Optival Health Solutions Private Limited, the Subsidiary Company has received four suspension orders of Drug License for stores situated at various locations in Hyderabad as mentioned below. Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, details is given below:

Name(s) of the Authority	Nature and details of the action(s) taken, initiated or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Details of the violation(s)/contravention(s) committed or alleged to be committed	Impact on financial operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
Assistant Director, Drugs Control Administration, Shameerpet, Secunderabad, Hyderabad, Telangana.	Suspension of Drug License for eight days each of stores (I to III) and six days store (IV) situated at: - (I) UCO Bank Colony Masabtank, (II) Gayathri Hills, Jubli Hills. (III) Rampally Circle, Medchal (IV) Poornodaya colony saidabad, Secunderabad.	Order received on 11.09.2024	Under Rule 65 & 66 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Potential Revenue Loss of Rs~10.05 Lacs, Rs~3.20 Lacs, Rs~2.82 Lacs, and Rs~5.74 Lacs respectively.

Kindly take the same on records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS 7460